- G1 Therapeutics Inc GTHX announced topline results from its pivotal Phase 3 PRESERVE 1 trial in patients with metastatic colorectal cancer.
- PRESERVE 1 was designed to evaluate the efficacy and safety of trilaciclib in addition to triplet therapy with FOLFOXIRI + bevacizumab.
- The trial achieved its co-primary endpoints related to severe neutropenia, showing clinically meaningful and statistically significant reductions in occurrences of severe neutropenia during induction (placebo=20% vs. trilaciclib=1%) and mean duration of severe neutropenia in Cycles 1 through 4 (1.3 days vs. 0.1 days).
- Also See: G1 Therapeutics Reveals An Early Cut Data From Bladder Cancer Trial.
- In addition, patients receiving trilaciclib had a clinically meaningful reduction in the rate of chemotherapy-induced diarrhea compared to placebo.
- Further, patients receiving trilaciclib experienced fewer chemotherapy dose reductions and delays.
- Other secondary measures of myeloprotection also favored trilaciclib, including reductions in Febrile Neutropenia (placebo=5% vs. trilaciclib=0%) and ESA administration (7% vs. 3%).
- However, early anti-tumor efficacy data favored the placebo arm versus trilaciclib, including overall response rate (ORR) and preliminary survival measures (61% and 50% ORRs, respectively).
- Given the differential in these anti-tumor efficacy metrics and the low likelihood of achieving the progression-free survival (PFS) and overall survival (OS) endpoints, the company will discontinue the colorectal (CRC) trial.
- Other clinical trials of trilaciclib in combination with different chemotherapies in patients with extensive-stage small-cell lung cancer and triple-negative breast cancer did not demonstrate this adverse survival signal.
- Price Action: GTHX shares are down 42.40% at $4.11 during the premarket session on the last check Monday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in
